Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors. Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities.

Testing for measurable residual disease can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia. Unfortunately, routine MRD testing is variable. This three-part webinar series is aimed at building capacity to implement, expand, and sustain MRD testing for patients with adult B-cell ALL at cancer programs and practices of all resource levels.

This on-demand webinar will take a deep dive into the differences between germline and somatic mutations and what this means for patients with cancer and their families.

A 3-member faculty panel will discuss treatment decisions for clinical case scenarios in advanced HR+ breast cancer. The panel will discuss challenging cases of patients and will offer guidance on evidence-based treatment choices for patients in the various lines of treatment and for managing treatment-related severe adverse events in these patients.

Learn more about the role of laboratory medicine professionals and pathologists, including a review of testing techniques and applications as well as lab-specific regulations and their impact on biomarker testing.

Hear finding and experiences of ACCC member programs who successfully orchestrated a quality improvement project to expand BRCA testing for eligible patients with breast cancer.

The Clinical Research Award recognizes individuals whose research has significantly and positively impacted the oncology patient, family, and/or community.

Optimal care delivery changes from place to place—what works best for one location and patient population may not be ideal for another. The same applies to cancer research. Understanding the needs of your patient population is critical to trial design and implementation. How can you proactively involve your community in cancer research activities? ​

With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.

Community cancer centers are fast becoming sites for biomarker testing and precision medicine. As clinical research becomes a larger part of community cancer center operations, strengthening tissue collection procedures and considering the establishment of biospecimen repositories are critical concerns.